Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Pfizer Inc | 722 |
| 2 | Boston Scientific Corp | 507 |
| 3 | Bristol Myers Squibb Co | 446 |
| 4 | Johnson and Johnson | 414 |
| 5 | Purdue Pharma LP | 377 |
| 6 | Medtronic PLC | 229 |
| 7 | Siemens AG | 198 |
| 8 | Novartis AG | 184 |
| 9 | University of California | 169 |
| 10 | Roche Holding AG | 161 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,028 |
| 2 | A61K | Medicinal preparations | 9,656 |
| 3 | C07D | Heterocyclic compounds | 6,541 |
| 4 | C07K | Peptides | 1,357 |
| 5 | G01N | Investigating / analysing materials | 1,178 |
| 6 | A61L | Sterilising / disinfecting materials | 1,034 |
| 7 | C07C | Acyclic and carbocyclic compounds | 1,017 |
| 8 | C08L | Polymer compositions (blends) | 868 |
| 9 | C12N | Microorganisms, enzymes | 819 |
| 10 | Y02A | Climate change adaptation | 618 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Synergistic compositions containing ketanserin | 1990 | Johnson and Johnson | 27 |
| Process for the dehydrogenative dimerization and/or polymerization of organic compounds with active hydrogen atoms using perketals | 1986 | Arkema SA | 7 |
| Process for preparing ketanserine | 1984 | 6 | |
| Cyclic perketals and their use for cross-linking high density polyethylene | 1981 | 6 | |
| Composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of CRPS | 2001 | Alfasigma SpA | 2 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 22 |
| 2017 | 21 |
| 2018 | 16 |
| 2019 | 26 |
| 2020 | 18 |
| 2021 | 15 |
| 2022 | 18 |
| 2023 | 13 |
| 2024 | 14 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gitte M. Knudsen | Rigshospitalet | 26 |
| 2 | Bertil Persson | Sahlgrenska University Hospital | 21 |
| 3 | Richard A. Glennon | Virginia Commonwealth University Medical Center | 16 |
| 4 | Claus Svarer | Copenhagen University Hospital | 11 |
| 5 | Lars H. Pinborg | Rigshospitalet | 10 |
| 6 | Takafumi Nagatomo | Niigata University of Pharmacy and Medical and Life Sciences | 10 |
| 7 | Vibe G. Frøkjær | Rigshospitalet | 9 |
| 8 | Julie C. Price | University of Pittsburgh | 8 |
| 9 | Jacek Borawski | Medical University of Białystok | 7 |
| 10 | Edward D. Levin | Duke Medical Center | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. | 1982 | 1079 | Synthesis and biological activity |
| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | 1998 | 1036 | Schizophrenia research and treatment |
| Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior | 2007 | 931 | Neurotransmitter Receptor Influence on Behavior |
| Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin | 1983 | 850 | Nitric Oxide and Endothelin Effects |
| Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors | 1981 | 845 | Neurotransmitter Receptor Influence on Behavior |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Ketanserin?
Which companies hold the most patents involving Ketanserin?
What was the publication volume trend for Ketanserin research in recent years?
What are the primary research topics associated with Ketanserin in the literature?
What patent applications relate to therapeutic uses of Ketanserin?